1. Home
  2. UCAR vs PPCB Comparison

UCAR vs PPCB Comparison

Compare UCAR & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$0.57

Market Cap

1.4M

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

HOLD

Current Price

$0.12

Market Cap

1.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
PPCB
Founded
2013
2007
Country
China
Australia
Employees
N/A
2
Industry
Retail-Auto Dealers and Gas Stations
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.4M
1.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
PPCB
Price
$0.57
$0.12
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$50.00
N/A
AVG Volume (30 Days)
25.1M
1.2M
Earning Date
05-14-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.10
52 Week High
$4.98
$10.69

Technical Indicators

Market Signals
Indicator
UCAR
PPCB
Relative Strength Index (RSI) 51.54 34.79
Support Level N/A N/A
Resistance Level $1.71 $0.40
Average True Range (ATR) 0.15 0.01
MACD 0.06 0.01
Stochastic Oscillator 35.16 41.34

Price Performance

Historical Comparison
UCAR
PPCB

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: